Intercell's acquisition of Iomai approved
This article was originally published in Scrip
Intercell's acquisition of Iomai was approved by the US-based vaccine specialist's shareholders in a meeting held on August 1st. Intercell will now acquire Iomai for $6.60 per share of the company's common stock, representing a total payment of $189 million. The acquisition, which is expected to close within the next few days, was approved by 99.97% of the votes cast, representing over 71% of the outstanding shares entitled to vote at the meeting.